PARP1 and triple-negative breast carcinoma: Currently, triple-negative breast cancer remains difficult to treat due to a lack of targeted therapies; however, PARP1 inhibitors are promising therapeutic options.34 Under certain conditions, SETD7 enhances PAPR1 enzymatic activity; thus, SETD7 inhibitors could synergize with PARP1 inhibitors to treat triple-negative breast cancer.